

## Mechanistic Insight Antidiabetic Potential of Ursolic Acid: *In-Silico* Molecular Docking

Priyanka Ashwar<sup>1</sup> & Jyoti K. Malik<sup>1</sup>  
 Institute of Pharmacy, P.U. University, Shriper (M.P.) India

**ABSTRACT:** Diabetes mellitus is a chief cause involved in the morbidity and mortality among the global population (Saeed et al., 2011). The main event of this syndrome includes elevated blood glucose level (hyperglycaemia) followed by polydipsia and polyuria. The secondary complications include renal damage, loss of kidney function and damage to nerves. Further, the diabetes mellitus will also increase the cardiovascular disease progression. Phytochemicals are as well one of the compounds occurring in plants. In this group Ursolic acid is a well recognized compound that is accessible from various sources like seeds as well as fruits and possess many types of activities and is a high candidate for developing novel treatment approaches for treating diseases. Thus, in the current study, ursolic acid a tetra-terpenoid was selected for evaluation of antidiabetic potential by molecular docking. A mechanistic insight for their antidiabetic potential is elucidating by interaction of ursolic acid with target protein.

**Keywords:** Diabetes mellitus, ursolic acid, in silico, in silico, glucose, glucose oxidase, Glycogen synthase kinase-3 (GSK-3).

Copyright © 2021 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### RESEARCH PAPER

\*Corresponding Author:  
 Priyanka Ashwar  
 Institute of Pharmacy, P. U.  
 University, Shriper (M.P.)  
 India

How to cite this paper:  
 Priyanka Ashwar & Jyoti K. Malik, "Mechanistic Insight Antidiabetic Potential of Ursolic Acid by *In-Silico* Molecular Docking", Middle East Res. J. Pharm. Sci., 2021, No. Dec-11(1), 1-11

Article History:  
 (Submitted: 04.11.2021)  
 (Accepted: 29.11.2021)  
 (Published: 27.12.2021)

## INTRODUCTION

Diabetes is a condition of the glucose, lipid, and protein metabolism that is brought on by decreased insulin production or developing resistance to the hormone's activity. Diabetes-related chronic hyperglycemia results in the ripening of body proteins, which then trigger secondary problems that damage the eyes, kidneys, nerves, and arteries [1]. Diabetes is associated with neurodegenerative and neurovascular problems, which are the main causes of morbidity and mortality in diabetic subjects, in addition to hyperglycemia and abnormalities in serum lipids [2]. Exercise, nutrition, and pharmaceutical medications can help manage it, but they can be expensive, have side effects, or have other limitations [3-4]. The search for safer and more efficient hyperglycemia medication. Diabetes mellitus represents a heterogeneous group of disorders. Some severe diabetic phenotypes can be categorized on the basis of specific evidence and in pathogenesis, but in many patients overlapping phenotypes make etiologic and pathogenic classification complicated [5].

### 1. Type 1 Diabetes Mellitus

It is an autoimmune disease in which the immune system destroys the

- Islet cells
- Pancreas

### 2. Type 2 Diabetes Mellitus

- Insulin resistance syndrome
- Hyperinsulinemic syndrome

### 3. Other specific types of Diabetes

- Genetic forms of diabetes (e.g. MODY, neonatal diabetes)
- Insulin deficiency (e.g. Type 1 diabetes mellitus)
- Insulin resistance syndrome (Metabolic syndrome)
- Autoimmune (e.g. autoimmune polyendocrine)
- Drug-induced (e.g. corticosteroids)
- Infection (e.g. congenital rubella)
- Hypophysial forms of endocrinopathies (e.g. null islet function)
- Idiopathic diabetes


### 4. Ursolic Acid

Ursolic acid (3-beta-O-hydroxy-urs-12-ene-28-oic acid) is a phytochemical and bioactive compound commonly found in several medicinal herbs and foods. Numerous pharmacological properties of UA have been

demonstrated in studies, including anti-inflammatory, hepatoprotective, anticancer, cardioprotective, neuroprotective, antimicrobial, antihyperlipidemic, anti-

diabetic, antifungal, antiviral, and reproductive effects [6].

**Description of ursolic acid [7]**

<b>IUPAC Name</b>	11S,20R,4aS,7aH,6aX,6bX,8aR,10S,12aR,14bS)-10-hydroxy-1,2,5a,6b,7,9,12a-heptaoxathyl-2,3,4,5,6,6a,7,8,9a,10,11,12,13,14b-trimethylheptanoic acid
<b>Structure</b>	
<b>Mol. Wt.</b>	456.7
<b>Mol. Formula</b>	C <sub>30</sub> H <sub>48</sub> O <sub>7</sub>
<b>M.P.</b>	247°C
<b>Solubility</b>	One part dissolves in 90 parts methanol, 178 acetone, 137 boiling alcohol, 140 ether, 388 chloroform, 1075 carbon tetrachloride. Moderately soluble in acetone. Soluble in benzene, glacial acetic acid and in 2% alcoholic NaOH. Insoluble in petroleum ether.
<b>Class</b>	terpenoids

**Biological effect of Ursolic acid [8]**



One of the most recent virtual screening techniques is molecular docking, particularly when the target protein's 3D structure is available. This technique was able to predict the structure of the protein-ligand complex as well as the binding affinity between the ligand and protein, which is important knowledge for lead optimization. Instead, for more than three decades, molecular docking has been used, and as a result, a large number of novel molecules have been found and developed [9]. Although molecular docking will undoubtedly continue to play a significant role, its

success rate is still far from being fully satisfied. High-throughput screening is still used often in many pharmaceutical companies today for this reason as well. Virtual screening based on docking would not be able to replace an irreplaceable. Thus, in the current investigation, ursolic acid a triterpenoid was selected for evaluation of anticancer potential by molecular docking. A mechanistic insight for drug anticancer potential is elucidating by interaction of ursolic acid with different target proteins.

**Allose Reductase**

The crystal structure of the allose reductase enzyme consisting of macromolecular receptor associated with bound ligand is downloaded

from the Protein Data Bank portal. All the primary information regarding receptor and structure (3s2g.pdb) registered in the Protein data bank was used. The bound ligand alucose was found within the receptor [16].



Figure 7: Crystal structure of allose reductase enzyme with bound ligand alucose (PDB ID-3s2g)

**Glycogen Synthase Kinase**

The crystal structure of the glycogen synthase kinase enzyme consisting of macromolecular receptor associated with bound ligand ARN25086 is downloaded

from the Protein Data Bank portal. All the primary information regarding receptor and structure (3o52.pdb) registered in the Protein data bank was used. The bound ligand ARN25086 was found within the receptor [17].




Figure 8: Crystal structure of glycogen synthase kinase enzyme with bound ligand ARN25086 (PDB ID-7iq5F)

**Molecular Docking Simulation Studies**

Docking of ligand uracilic acid was performed against α-glucosidase, α-amylase, allose reductase, and glycogen synthase kinase-3 enzyme was performed by AutoDock to establish its probable mechanism of action. All the bonds of ligand uracilic acid were kept flexible, while no residues in receptor were made flexible [18].

**Toxicity & ADME-T Studies**

The pharmacokinetics of ligand molecule was studied by online program OSIRIS, for prediction of presence of any toxic group as well as presence of any toxic group and ADME-T properties [19].

**RESULT AND DISCUSSION**

Diabetes mellitus (DM) is a chronic condition of carbohydrate metabolism that results in high blood glucose levels from an impaired glucose homeostasis. On a global scale, diabetes mellitus (DM) is acknowledged as one of the most serious diseases of the twenty-first century. Curiously, a variety of oral hypoglycemic medications have been used to manage this condition. These medications are grouped into different classes and include biguanides, sulfonylureas, meglitinides (TZD), meglitinids, incretin/peptidase (IV) inhibitors, sodium-glucose cotransporter (SGLT2), and α-glucosidase inhibitors. Each class has a distinct method of action and is directed at a certain kind of sugar. In reality, to treat the condition


**EXPERIMENTAL WORK**

**Molecular docking studies**

**Ligand Preparation**

2D Structure of ligand ursolic acid was drawn by using ChemDraw [10]. The two-dimensional a

structure of ligand was converted into 3D structure with optimized 3D geometry by using Chem3D software. The optimized structure was saved in PDB format for AutoDock compatibility [11].



**2D and 3D structure of ursolic acid**


**Preparation of the grid file**

The regions of interest used by *Schrodinger* were defined by surrounding grid area by making a grid box around the active sites. Grid box plays a central role in process of docking as it is made to cover all the amino acids present in active sites necessary for binding with


that drug present in receptor. Grid box has 3 dimensional grids which let us change the number of points in the x, y and z dimensions. The spacing between grid points can be adjusted with another dimension, the value in the study taken is given in table 1 [12].

**Table 1: The grid-coordinates of the grid-box used in the current study**

Protein	x-D	y-D	z-D	spacing (Å)	x center	y center	z center
3wyl	50	50	50	0.397	31.937	24.799	22.743
5emy	40	40	40	0.442	-13.934	-16.743	24.123
3xlg	40	40	40	0.397	8.851	9.014	18.39
7ox3	40	40	40	0.392	23.936	17.106	9.189



**Figure 1: Grid box covering all active sites in  $\alpha$ -glucosidase enzyme (3wyl).**



**Figure 2: Grid box covering all active sites in  $\alpha$ -amylase enzyme (5emy).**